Glaukos Corp.

GKOS

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001192448

B/C

on the B/C boundary of 305 graded peers in healthcare

rank 116 of 305; percentile 37.8; sampling error 2.8 points; lower is stronger



B/C, the elk



Scoreboard	
Profitability	C percentile 50.8
Solvency	B/C percentile 37.9
Growth and financing	B/C percentile 42.3
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $893.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	8 of 13
Graded from	filings received through Feb 23, 2026 268 days before the rescan; latest periodic filing 10-Q received Oct 28, 2026
Last close	$243.24 2026-11-17; market equity $14.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 50.8						
Gross profitability	31.6%	32.8%		47.5	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

a prior annual debt, equity, and cash observation is required						
Accruals ratio	(18.5%)	(6.7%)		22.4	756	2025-12-31
Gross margin stability, five years	8.2 pts	2.8 pts		82.6	237	2025-12-31
Solvency, sleeve percentile 37.9						
Altman Z double-prime	0.74	0.31		35.5	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(3.61x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.69x	2.68x		40.4	781	2025-12-31
Growth and financing, sleeve percentile 42.3						
Revenue growth, three-year compound	21.5%	9.6%		30.1	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
NOPAT must exceed $100,000						
Asset growth, three years	(3.8%)	3.2%		61.0	663	2025-12-31
Net share issuance, one year	2.7%	1.6%		35.7	625	2026-02-18

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 11,876,000 USD; Altman Z is not used

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
111	Koru Medical Systems, Inc. (KRMD)	36.2	B	fortress balance sheet
112	BrightSpring Health Services, Inc. (BTSG)	36.5	B	
113	Ionis Pharmaceuticals Inc. (IONS)	36.8	B	
114	Apyx Medical Corp. (APYX)	37.2	B	
115	ImmunityBio, Inc. (IBRX)	37.5	B/C	short runway, distress
116	Glaukos Corp. (GKOS)	37.8	B/C	fortress balance sheet
117	Insmed Inc. (INSM)	38.2	B/C	
118	Fitlife Brands, Inc. (FTLF)	38.5	B/C	
119	Myomo, Inc. (MYO)	38.8	B/C	fortress balance sheet
120	Tenet Healthcare Corp. (THC)	39.1	B/C	
121	Establishment Labs Holdings Inc. (ESTA)	39.5	B/C	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	86.4%	(1.7%)	88
Distance from 52-week high	(1.6%)	(30.5%)	94
EBIT to enterprise value	(1.4%)	0.5%	44
Free cash flow yield	(0.2%)	0.5%	46
Book value to price	0.05	0.28	17
Sales to price	0.04	0.36	7
Composite equity issuance, five years	25.7%	13.5%	62
Relative strength against the sector, log excess return	0.45	(0.19)	88
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$162.3M
Operating cash flow, four quarters	$47.7M
Months of runway	not finite
Days since last periodic filing	21 (10-Q received Oct 28, 2026)
Median daily dollar volume, 63 sessions	$150.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$282.8M	2025-12-31	2026-02-23	10-K	26-061944
2	assets	us-gaap:Assets	$893.5M	2025-12-31	2026-02-23	10-K	26-061944
3	operating income	us-gaap:OperatingIncomeLoss	-$10.3M	2015-12-31	2018-02-28	10-K	18-001301
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$38.3M	2015-12-31	2018-02-28	10-K	18-001301
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$33,000	2015-12-31	2018-02-28	10-K	18-001301
6	total debt	us-gaap:LongTermDebt	$9.7M	2015-12-31	2017-03-15	10-K	17-001833
7	book equity	us-gaap:StockholdersEquity	$95.2M	2015-12-31	2016-03-15	10-K	16-004119
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$21.6M	2015-12-31	2018-02-28	10-K	18-001301
9	net income	us-gaap:NetIncomeLoss	-$187.7M	2025-12-31	2026-02-23	10-K	26-061944
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.8M	2025-12-31	2026-02-23	10-K	26-061944
11	assets	us-gaap:Assets	$974.8M	2024-12-31	2026-02-23	10-K	26-061944
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$507.4M	2025-12-31	2026-02-23	10-K	26-061944
13	gross profit	us-gaap:GrossProfit	$289.5M	2024-12-31	2026-02-23	10-K	26-061944
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$383.5M	2024-12-31	2026-02-23	10-K	26-061944
15	gross profit	us-gaap:GrossProfit	$239.1M	2023-12-31	2026-02-23	10-K	26-061944
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$314.7M	2023-12-31	2026-02-23	10-K	26-061944
17	gross profit	us-gaap:GrossProfit	$213.9M	2022-12-31	2025-02-25	10-K	25-001402

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$282.9M	2022-12-31	2025-02-25	10-K	25-001402
19	gross profit	us-gaap:GrossProfit	$227.4M	2021-12-31	2024-02-23	10-K	24-001630
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$294.0M	2021-12-31	2024-02-23	10-K	24-001630
21	current assets	us-gaap:AssetsCurrent	$475.0M	2025-12-31	2026-02-23	10-K	26-061944
22	current liabilities	us-gaap:LiabilitiesCurrent	$101.3M	2025-12-31	2026-02-23	10-K	26-061944
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$933.1M	2025-12-31	2026-02-23	10-K	26-061944
24	operating income	us-gaap:OperatingIncomeLoss	-$199.6M	2025-12-31	2026-02-23	10-K	26-061944
25	book equity	us-gaap:StockholdersEquity	$656.2M	2025-12-31	2026-02-23	10-K	26-061944
26	liabilities	us-gaap:Liabilities	$237.3M	2025-12-31	2026-02-23	10-K	26-061944
27	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$4.3M	2015-12-31	2018-02-28	10-K	18-001301
28	operating income	us-gaap:OperatingIncomeLoss	-$128.7M	2023-12-31	2026-02-23	10-K	26-061944
29	interest expense	us-gaap:InterestExpense	$13.6M	2023-12-31	2024-02-23	10-K	24-001630
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.7M	2025-12-31	2026-02-23	10-K	26-061944
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$61.3M	2024-12-31	2026-02-23	10-K	26-061944
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.3M	2024-12-31	2026-02-23	10-K	26-061944
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$57.8M	2023-12-31	2026-02-23	10-K	26-061944
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$20.2M	2023-12-31	2026-02-23	10-K	26-061944
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$33.1M	2022-12-31	2025-02-25	10-K	25-001402
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$30.3M	2022-12-31	2025-02-25	10-K	25-001402
37	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$38.1M	2025-12-31	2026-02-23	10-K	26-061944
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$193.0M	2025-12-31	2026-02-23	10-K	26-061944
39	income tax	us-gaap:IncomeTaxExpenseBenefit	-$5.4M	2025-12-31	2026-02-23	10-K	26-061944
40	current assets	us-gaap:AssetsCurrent	$449.8M	2024-12-31	2026-02-23	10-K	26-061944
41	current liabilities	us-gaap:LiabilitiesCurrent	$75.1M	2024-12-31	2026-02-23	10-K	26-061944
42	assets	us-gaap:Assets	$940.4M	2023-12-31	2025-02-25	10-K	25-001402
43	assets	us-gaap:Assets	$1.0B	2022-12-31	2024-02-23	10-K	24-001630
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,078,812	2026-02-18	2026-02-23	10-K	26-061944
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	56,567,386	2025-02-19	2025-02-25	10-K	25-001402

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.